Key facts
- This page summarizes Dwight H. Egan's Form 4 filing for Co-Diagnostics, Inc. (CODX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 25 May 2022, 13:32.
Dwight H. Egan - 23 May 2022 Form 4 Insider Report for Co-Diagnostics, Inc. (CODX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- CODX
- Reported as of
- 23 May 2022
- Net transaction value
- -$59,151
- SEC form
- 4
- Accepted by SEC
- 25 May 2022, 13:32:32 UTC
- Prior SEC filing
- 24 Nov 2021
- Next SEC filing
- 07 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dwight H. Egan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Dwight H. Egan filed Form 4 for Co-Diagnostics, Inc. (CODX) on 25 May 2022.
Change
- Previous filing in this sequence was filed on 24 Nov 2021.
- Current net transaction value: -$59,151.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CODX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +33,334
- Change %
- +135%
- Price
- $0.000000
- Shares after
- 57,995
- Date
- 23 May 2022
- Ownership
- Direct
- Footnotes
- F1
CODX
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $59,151
- Shares
- -11,854
- Change %
- -20%
- Price
- $4.99
- Shares after
- 46,141
- Date
- 23 May 2022
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CODX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -33,334
- Change %
- -22%
- Price
- $0.000000
- Shares after
- 120,833
- Date
- 23 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 154,167
- Exercise price
- $0.000000
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Included in 75,000 restricted stock units awarded to the Reporting Person on November 23, 2020, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on May 24, 2021. Included in 125,000 restricted stock units awarded to the Reporting Person on August 12, 2021, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on November 23, 2021.
Footnote F2
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.